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ABSTRACT 
 
ANTIDEPRESSANT USE AND RISK OF COLORECTAL CANCER IN THE 
WOMEN’S HEALTH INITIATIVE 
MAY 2016 
JENNA F.  KIRIDLY, B.A., BOSTON UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Katherine Reeves 
Colorectal cancer is the third most common cancer among U.S. women; 63,610 
new cases were estimated to have occurred in 2015. Prior studies found a reduced risk of 
colorectal cancer among antidepressant (AD) users, however, none adjusted for 
depression, which is itself linked to increased colorectal cancer risk and could confound 
this relationship. We assessed associations between ADs and AD drug classes with the 
risk of colorectal cancer in a prospective cohort of 145,190 women ages 50-79 without a 
previous history of cancer at enrollment. Current AD use was assessed at baseline. Over 
an average follow-up of 14 years, 5,280 cases of colorectal cancer cases were diagnosed 
and 6.9% of women were AD users. Cox proportional hazard ratios, adjusted for 
colorectal cancer risk factors including depressive symptoms, were used to model the 
associations. Of all AD users, 51.1% used selective serotonin reuptake inhibitors (SSRIs), 
40.7% used tricyclic antidepressants (TCAs), and 15.1% used other ADs.  No association 
was seen between total AD use, SSRI use, and/or other ADs and risk of colorectal cancer. 
We observed a reduced risk of colorectal cancer among TCA users, which was significant 
for colon cancer specifically (HR 0.68, 95% CI: 0.48-0.96).  Although a reduced risk of 
colon cancer was observed for individuals who used TCAs for less than two years (HR 
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0.42, 95% CI: 0.22-0.81), no association was observed for individuals who used for two 
or more years (HR 0.97, 95%CI: 0.69-1.37). Our data suggests a protective association 
between TCA use and risk of colorectal cancer, however more research is needed to 
verify these findings.  These results show no negative effects of AD in relation to 
colorectal cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
TABLE OF CONTENTS 
           
                  Page 
ACKNOWLEDGEMENTS ..............................................................................................  iii 
ABSTRACT .........................................................................................................................v 
LIST OF TABLES ........................................................................................................... viii 
CHAPTER 
1. INTRODUCTION ...................................................................................................2 
2. METHODS ..............................................................................................................5 
          2.1 Study Population ..................................................................................................5 
          2.2 Exposure Assessment...........................................................................................6 
          2.3 Outcome Assessment ...........................................................................................6 
          2.4 Covariate Assessment ..........................................................................................7 
          2.5 Statistical Analysis ...............................................................................................8 
3. RESULTS ..............................................................................................................11 
4. DISCUSSION ........................................................................................................13 
5. CONCLUSION ......................................................................................................20 
BIBLIOGRAPHY ..............................................................................................................29 
  
viii 
 
LIST OF TABLES 
Table                 Page 
1. Distribution of Covariates by Antidepressant (AD) use; Women’s Health Initiative  
   (WHI) ..............................................................................................................................21 
 
 
2. Distribution of AD Subtype Use Among Antidepressant Users (N=10,036); WHI ......23 
 
 
3. Distribution of Colorectal Cancer According to Antidepressant Use; WHI..................24 
 
 
4. Age and Multivariable Adjusted HRs and 95% Confidence intervals of Baseline AD    
    use and Colorectal Cancer; WHI ...................................................................................25 
 
 
5. Age and Multivariable adjusted HRs and 95% Confidence intervals of Baseline AD  
    use and Colon Cancer; WHI ..........................................................................................25 
  
 
6. Age and Multivariable adjusted HRs and 95% Confidence intervals of Baseline AD  
    use and Rectal Cancer; WHI ..........................................................................................27 
 
 
7. Multivariable adjusted HRs and 95% Confidence Intervals for the Joint Distribution of  
    Depressive Symptoms and AD use at Baseline and risk of Colorectal Cancer;  
    WHI................................................................................................................................28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
CHAPTER 1 
 
INTRODUCTION 
Colorectal cancer is the third most common cancer among U.S women, 63,610 new cases 
were estimated to have occurred in 2015.1 Older women, ages 50-70, have a considerably higher 
risk of developing colorectal cancer as compared to younger women.1  Antidepressant (AD) use 
is also common among older women, with 23% of women ages 40-59 and 18.6% of women ages 
60 and over taking ADs according to the National Health and Nutrition Examination Survey 
(2008).2 Among those treated with ADs, selective serotonin reuptake inhibitors (SSRIs) are the 
most common, whereas tricyclic antidepressants (TCAs) and other antidepressants have become 
less common, since 1995.3   Roughly 78% of ADs are prescribed for depression, however other 
uses of ADs include mood disorders, anxiety, and chronic pain.4, 5   Compared to healthy 
individuals, women with depression have high levels of inflammatory markers, which may lead 
to a 40% increased risk of colorectal cancer.6,7  Furthermore, women with depression are more 
likely to have risk factors of colorectal cancer such as higher body mass index (BMI), poor diet 
(i.e. high fat, low fiber diets), smoking, drinking, and physical inactivity.6, 7 This is important as 
depression is highly related to AD use and studies suggest that depression may lead to 
inflammatory and behavioral risk factors for colorectal cancer; thus, to determine the true effects 
of AD use on risk of colorectal cancer we must consider the effects of depression.  
Whether AD use influences colorectal cancer remains unclear. Several studies have 
reported decreased risk of colorectal cancer among regular AD users compared to non-users.8-12 
When SSRIs and TCAs were examined separately, three out of five studies observed strong 
inverse associations between SSRIs and risk of colorectal cancer.8,9,12 A significant reduction in 
risk of colorectal cancer was observed among SSRI users taking a high cumulative dose (>0.01 
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mol) within the five years before diagnosis (OR 0.69, 95% CI: 0.50-0.96)12 and among regular 
users of SSRIs (taking SSRIs consecutively for three months) (OR 0.55, 95% CI: 0.35-0.88) 
when compared with non-users.9 Another study observed a non-statistically significant reduced 
risk among SSRI users, specifically among those using SSRIs for less than 2 years.8 Conversely, 
two studies found no association between SSRIs and risk of colorectal cancer when considering 
different intensities and durations of use.10,11 
Studies which examined the effects of TCA use on risk of colorectal cancer were 
similarly unclear. A non-significant reduction of colorectal cancer was observed among regular 
TCA users (OR 0.77, 95% CI: 0.52-1.16), 9 regardless of duration of use.8, 9 Conversely, a record 
linkage study that looked at non-SSRI use, much of which is likely TCAs, found a non-
significant increased risk of colon cancer within the highest category (1460 mg average 
maintenance dose per day) as compared to users within the lowest category (RR 2.19, 95% CI: 
0.85-5.66 and RR 2.03, 95% CI: 0.83-4.96 respectively).11 Furthermore, a separate case-control 
study found no association between TCAs and colorectal cancer when considering various 
intensities and duration of use.10   
Laboratory studies support a possible protective effect of SSRIs on colorectal cancer. 
Elevated levels of serotonin have been hypothesized to play a role in colorectal cancer, 
promoting cell division of adenocarcinomas of the large intestine. SSRIs act as an antagonist, 
inhibiting the reuptake of serotonin, reducing the mitotic rate of tumor cells within the colon.12, 13 
Laboratory studies examining the effects of TCAs on colorectal cancer have been less clear, as in 
vitro studies of the effects of TCAs on human carcinoma cell lines have shown evidence to 
support both an increase and decrease in the risk of colorectal cancer.8 
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Prior epidemiologic studies of colorectal cancer have not considered depression and AD 
use together, despite the high concordance between these exposures. As mentioned previously, 
78% of AD users take ADs for depression. Additionally, depression may lead to the increased 
appearance of behavioral and inflammatory risk factors for colorectal cancer, confounding the 
relationship between AD use and risk of colorectal cancer.7, 14- 17 Additionally, prior studies have 
relied on either prescription records or self-report to assess AD use.8-12 While prescription 
records provide information on dosage and duration, they might not reflect compliance and 
actual use.  Within the Women’s Health Initiative (WHI) information on current medication use 
was assessed at baseline via an in-person interview to which participants brought their current 
pill bottle, aiding in verification of AD exposure. Information on duration of use was also 
available through self-report. Additionally, the WHI has extensive information available on 
potential confounders including depressive symptoms. Therefore, we examined the influence of 
AD use on risk of colorectal cancer in the WHI cohort.  We hypothesized that AD use, 
particularly SSRI use, would be associated with a reduced risk of colorectal cancer.  
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CHAPTER 2 
METHODS 
2.1 Study Population 
 The WHI began with the enrollment of 161,808 postmenopausal women aged 50-79 
between 1993 and 1998. Briefly, recruitment of participants took place at 40 clinical centers in 
24 states, including the District of Columbia and nationally at the National Institute of Health’s 
Clinical Coordination Center.18  
 The WHI is divided into two study arms, a randomized clinical trial (CT) and an 
observational study (OS). Women could not participate in both the observational and clinical 
trial arm. The randomized clinical trial (N=68,132)18 focused on prevention strategies and 
consisted of three components: 1) hormone therapy trials, 2) a dietary modification trial, and 3) a 
calcium and vitamin D trial. Women eligible for the clinical trial arm were randomized into one, 
two, or all three components. Women who were not eligible18 for the clinical trial were invited to 
join the observational study.    The observational study (N=93,676)18 examined the relationship 
between lifestyles, health and risk factors, and specific disease outcomes. The medical history 
and health habits of the women in this arm were followed through 2005.  
Eligibility criteria that was the same for both arms of the WHI was defined as being 
between the ages of 50-79, postmenopausal, and planning to reside within the study area for at 
least three years after enrollment.  If participants had a pre-existing medical condition that was 
predictive of a survival time less than three years, a condition that could interfere with 
consistency or adherence, or if they were currently participating in another randomized control 
trial they were excluded from both the CT and OS.18 Exclusion criteria for this analysis included 
missing information on AD use (n=2), and/or missing information on follow-up time (n=691). 
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No participants had missing information on diagnosis of colorectal, colon, or rectal cancers.  
Further, participants were excluded from our analysis if they had a previous history of any cancer 
(n=15,925), with the exception of those with non-melanoma skin cancer. Primary analysis 
consisted of 145,190 women with an average length of follow up time of 14.3 years.  
2.2 Exposure Assessment - Antidepressant use 
AD use was assessed at baseline. Women were asked to bring in all current prescription 
medications to in-person interviews. Information on AD medication name and duration of use 
was documented19 by clinical interviewers into a database, using Medi-Span software (First 
Databank inc., San Bruno, CA), which assigned Therapeutic Class Codes (TCCODE) to 
medications used regularly (for at least two weeks). Duration of use was self-reported.20 For our 
analysis, women were categorized as AD users or non-AD users at baseline. Additionally, we 
considered AD use by drug class (SSRIs, TCAs, and other ADs) and evaluated the impact of 
duration of AD use (e.g., use for up to two years, or use for greater than two years). Duration was 
dichotomized by median years of use for ADs. For comparison purposes median cuts for ADs 
were applied across all AD subgroups (SSRI, TCA, and other AD).8-10  
2.3 Outcome Assessment- Colorectal cancer 
Our outcome was the occurrence of colorectal, colon, rectal, and/or recto-sigmoid cancer 
through follow-up (2005). Details of outcome assessment, including adjudication procedures in 
the WHI, have been described elsewhere.21 In short, colorectal, colon, rectal and recto- sigmoid 
cancers were self-reported on a semiannual basis for CT participants and annually for OS 
participants through 2005. Medical records were collected for physician adjudication according 
to standardized criteria. Primary colorectal cancer diagnosis was confirmed through review of 
pathology reports, and additional information by trained coders at the WHI clinical coordinating 
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center. Tumor registry coders determined grade and stage of the tumor and assigned appropriate 
codes. Only colorectal, colon, rectal, recto sigmoid cases confirmed by adjudication were 
included in these analyses. Rectal cancer cases consisted of both rectal and recto-sigmoid 
cancers.22-23 
2.4 Covariate Assessment 
Covariates were selected based on inclusion in prior literature and known risk factors for 
colorectal cancer and AD use (Table 1).8-12 Age, race and ethnic subgroup (White (not Hispanic, 
Asian Pacific Islander, Black, Hispanic/ Latino), smoking status (never, <5 pack-years, 5-20 
pack-years, >20 pack-years, don’t know duration of smoking), diabetes, diverticulitis, 
hypertension, primary care provider, hormone replacement therapy (HRT) use (never, past 
estrogen-alone, past estrogen and progesterone, current estrogen, current estrogen and 
progesterone), involvement in hormone therapy study arm of WHI, physical activity (MET-
hours/week (quartiles)), family history of colorectal cancer, early screening for colorectal cancer, 
and polyp removal were obtained through self-administered forms at baseline. Drinking habits 
were abstracted from a food frequency questionnaire and categorized as (none, past <1 drink per 
month, <1 drink per week, 1-7 drinks per week, 7+ drinks per week). Current use or non-use of 
non-steroidal- anti-inflammatory drugs (NSAIDs) was collected during an in-person interview at 
a baseline and recorded in a database. For this analysis, duration of NSAID use was categorized 
as <1 year, 1-3 years, 3-8 years, and 8-20 years.  BMI was calculated from height and weight 
measurements during a screening visit (Underweight (<18.5 kg/m2), Normal (18.5-24.9 kg/m2), 
Overweight (24.9-<30 kg/m2), Obese I (30-34.9 kg/m2), Obese II (35.0-39.9 kg/m2), Extreme 
Obese (40kg/m2)). The healthy eating index score (HEI2005 (quartiles)) was used as a measure 
of diet quality and was calculated via food frequency questionnaires. 
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Information on depressive symptoms was self-reported at baseline using the Burnam 
eight item scale, 24 which contained six items from the Center for Epidemiologic Studies 
Depression Scale (CES-D) and two items from the National Institute of Mental Health’s 
Diagnostic Interview Schedule.  The six items from the CES-D assessed the frequency of 
depressive symptoms within the last week, while the two items from the National Institute of 
Mental Health assessed depressive symptoms within the last year or two.25 Consistent with prior 
studies in the WHI, 26, 27 the Burnam score was categorized into two groups (< 0.06 and ≥ 0.06), 
to classify women as experiencing depressive symptoms consistent with women with clinical 
depression. The Burnam scale was found to have 74% sensitivity and 87% specificity when 
compared to clinical diagnosis of depression.25  
2.5 Statistical Analysis  
Participants were categorized by AD use (AD user, non-AD user) at baseline to examine 
the distribution of covariates between participants (Table 1).  Additionally we examined the 
distribution of AD drug class (Table 2) and colorectal cancers (Table 3) by AD use. To examine 
the distribution of drug class, covariates, and colorectal cancers by AD use, we used chi square 
tests and t-tests as appropriate. 
We used multivariable Cox proportional hazards regression to estimate hazard ratios 
(HR) and 95% confidence intervals (CI) of the association between AD use and time to 
colorectal cancer diagnosis while adjusting for potential confounders. In these analyses, women 
were followed from enrollment through 2005, contributing person-time to the analysis until 
diagnosis of colorectal, colon, or rectal cancers, death, loss-to follow-up, or the end of the study/ 
administrative censor date defined as the participants last available date, whichever happened 
first. We separately examined the relationship between AD use and the risks of colon cancer and 
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rectal cancer, and evaluated the associations between subgroups of ADs most commonly used in 
this cohort (SSRIs, TCAs, and other ADs) and colorectal cancer. We additionally examined the 
effects of duration of AD use, including duration of SSRIs, TCAs, and other ADs. 
To further evaluate the effects of depression on the relationship of AD use and risk of 
colorectal cancer, we examined the joint distribution of AD use and depression within our 
multivariable model, estimating HR and 95% confidence intervals. Our primary variable for the 
model was broken into those with no depressive symptoms and no AD use, no depressive 
symptoms and AD use, depressive symptoms and no AD use, and depressive symptoms and AD 
use.  Additionally, we conducted a stratified analysis to evaluate whether the relationship of AD 
use and risk of colorectal cancer varied by strata of depression (depressive symptoms vs no 
depressive symptoms). To test the overall significance of the interaction, we included an 
interaction term in our multivariable model and used the likelihood ratio test to compare the full 
and reduced models.  
Variables were selected for our preliminary model based on univariate analyses and prior 
literature; 8-12 variables with a log rank ratio test p-value ≤ 0.25 were included in our initial 
multivariable model.  In our final model, likelihood ratio tests were completed for all remaining 
variables; selected covariates were chosen based on p-values (p ≤0.05). Our final model was 
adjusted for age, smoking status, diabetes, HRT use, physical activity (MET-hours/week 
(quartiles)), family history of colorectal cancer, early screening for colorectal cancer, polyp 
removal, NSAID use, HRT study arm, depression, and BMI, as described above. Due to the fact 
that BMI 28, age 28, and HRT arm 29 are known to have associations with colorectal cancer, they 
remained in the model regardless of p-value.  To further examine the independent relationships 
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of age, BMI and depression, we created three separate models; age adjusted, age and BMI 
adjusted, and age, BMI, and depression adjusted. 
Two sided p-values (p≤ 0.05) were considered statistically significant. This analysis was 
performed with STATA version 14.0 (Stata Corporation, College Station, TX).   
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CHAPTER 3 
RESULTS 
After all exclusions, 145,190 participants of the Women’s Health Initiative were included 
in our analyses, of which 135,154 (93.1%) women were non-users of antidepressant (AD) at 
baseline while 10,036 (6.9%) women were current AD users at baseline. 
Distribution of baseline covariates by AD use are presented in Table 1. At baseline, 
29.2% of women who were current AD users and 9.4% of non-users were experiencing 
depressive symptoms. Overall, current AD users tended to be younger at enrollment, obese, be 
current smokers, have a poor diet, and be physically inactive as compared to non-users.  Also, a 
greater percentage of AD users self-reported health complications such as diabetes (8.5% vs. 
5.6%), diverticulitis (11.8% vs. 7.9%), and hypertension (40.3% vs. 32.7%).  Women who were 
current AD users were more likely to have a health care provider who they had visited within the 
last year as compared to non-users (91.5% vs 80.8%). Furthermore, AD users were more likely 
to have had a recent colonoscopy within the last five years (41.1% vs 31.0%) and, among those 
who had a colonoscopy, to have had a polyp removed (18.8% vs 16.7%). Concurrent use of non-
steroidal anti-inflammatory drugs (NSAIDs) or postmenopausal hormonal therapy was higher 
among AD users versus non-users.   
Among AD users, the most common treatment was SSRIs (51.1%), followed by TCAs 
(40.7%), and other antidepressants (15.1%) (Table 2). Additionally, some women reported use of 
more than one AD, with 303 taking TCAs and SSRIs, 312 taking SSRIs and some other AD, 81 
taking TCAs and some other AD, and 7 women taking all three (data not shown).   
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During the study follow-up period, 2,580 women were diagnosed with colorectal cancer 
(Table 3) including 2,150 cases of colon cancer, 149 cases of recto-sigmoid cancer, and 341 
cases of rectal cancer; 60 women had more than one type of colorectal cancer (data not shown). 
Results from age adjusted and multivariable adjusted Cox proportional hazard regression 
models are presented in Table 4. In our multivariable-adjusted model, we observed a borderline 
significant reduced colorectal cancer risk associated with TCA use (HR 0.76, 95% CI: 0.56-
1.03), although no association was observed with total AD use (HR 0.90, 95% CI: 0.75-1.09), 
SSRI use (HR 1.08, 95% CI: 0.85-1.36), or use of other ADs (HR 0.63, 95% CI: 0.53-1.11). The 
decreased risk associated with TCA use was observed among women using the drug for less than 
two years (HR 0.42, 95% CI: 0.22-0.81) but not among those using the drug for longer duration 
(HR 0.97, 95% CI: 0.69-1.37). 
Similarly, TCA use was associated with a decreased risk of colon cancer (HR 0.68, 95% 
CI: 0.48-0.96; Table 5), with the strongest effect seen among short-term users (HR 0.39, 95% CI: 
0.19-0.82). Total AD use (HR 0.91, 95% CI 0.74-1.12), SSRI use (HR 1.17, 95% CI 0.91-1.5), 
and other AD use (HR 0.56, 95% CI: 0.29-1.08) were not associated with risk of colon cancer. 
No significant association was observed between AD use with risk of rectal cancer (Table 6). 
We also explored how AD use affected colorectal cancer risk among women with and 
without depressive symptoms (Table 7). There was no statistically significant interaction 
between AD use and depressive symptoms on risk of colorectal cancer (p=0.92) (data not 
shown). However, in a model with a joint definition of AD use and depression, we did observe a 
suggestive increased colorectal cancer risk among women experiencing depressive symptoms 
without AD use (HR 1.21, 95% CI: 1.05-1.4) compared to women with neither depressive 
symptoms nor AD use. 
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CHAPTER 4 
DISCUSSION 
In this prospective study of postmenopausal women, we observed a statistically 
significant 32% reduced risk of colon cancer among TCA users, though this effect was limited to 
those using TCAs for less than two years.  A similar decreased risk of rectal cancer was observed 
among TCA users using for less than two years, however results were limited by small numbers 
and were not significant. Overall, we found no compelling evidence of an association between 
total AD use, SSRIs, or other ADs on the risk of colorectal, colon, or rectal cancers specifically.  
Prior evidence of the relationship between TCAs and colorectal cancer is contradictory. 
Some epidemiological studies of TCA use found non-significant reductions of colorectal cancer, 
8, 9 while others observed no association.10, 12 A case-control study which enrolled 649 cases from 
an integrated healthcare delivery system (N=1,305), observed a reduced risk of colorectal cancer 
among TCA users (OR 0.7, 95% CI: 0.5-1.1), and those using the drug for less than two years 
(OR 0.6 95% CI: 0.3-1.0).8  Additionally, in another case control study, a non-significant 
reduced risk of colon cancer among TCA users (OR 0.81, 95% CI: 0.51-1.29) was observed 
(N=10,011).9 Conversely, two studies found no association between TCA use and risk of 
colorectal cancer.10, 12 Differences between our analysis and previous studies may be due to their 
smaller sample size, which limited their ability to detect an association between TCA use and 
risk of colorectal cancer.8, 9 Additionally, we were able to control for important potential 
confounders, (i.e. depression, colonoscopy history, and polyp removal) which may have 
enhanced our ability to see a true effect. Limited control of confounding factors, particularly 
depression, may have reduced the ability of previous studies to observe the independent effect of 
TCA use on colorectal cancer risk.8-12 Further, our observation of an inverse association between 
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colorectal cancer and TCA use was restricted to current users, and was not observed among 
longer term users, which raises some concern about whether the association is real. Prior studies 
measured AD use through pharmacy records or databases.8-12 In the WHI, however, women were 
asked to bring in current medications to their clinical visit, and self- report duration of use.  
While this has the advantage of capturing current use, it may not reliably capture past use or 
adherence. Pharmacy records are similarly limited in this fashion as participants could have filled 
prescriptions and not taken prescribed ADs, or they could have been taking them inconsistently.  
This misclassification of use could have led in part to the null results observed by previous 
studies10, 12 and the null findings of studies which looked at use for greater than 2-3 years.8, 9 
Additionally, misclassification of use could have attenuated our ability to detect a true 
association between AD use and risk of colorectal cancer, particularly when considering duration 
of use greater than two years, and may in part account for our null findings in this group.  
 In contrast to our null association between SSRI use and colorectal cancer, some previous 
studies observed a reduced risk of colorectal cancer among SSRI users.8, 9, 12 One case-control 
study reported that regular users of SSRIs had a significant decrease in risk of colorectal cancer 
(OR 0.55, 95% CI: 0.35-0.88) and colon cancer (OR 0.47, 95% CI: 0.26-0.85) when compared 
with non-users.9 Similar results were seen among SSRI users taking a high cumulative dose 
(>0.01 mol) within the five years before diagnosis (OR 0.69, 95% CI: 0.50-0.96).12 Another 
study found a similar reduced risk (OR 0.7 05% CI 0.4-1.1) of colorectal cancer among SSRI 
users, however results were not significant.8 Differences in the results of this current analysis as 
compared to previous work may be due to the timing and study design. Previous studies,8-12 
collected information retrospectively from pharmacy databases on SSRI use within the 10-20 
years before colorectal cancer diagnosis, occurring in 200012, 20038, and or 2008.9,10 In contrast, 
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our study design assessed AD use once, at baseline, and followed women forward until 
development of colorectal cancer, death, or end of the study period. As use of SSRIs as treatment 
for depression became more prevalent after 1995, many SSRI users may have been new users at 
baseline exposure assessment, in 1993. Recency of SSRI exposure may have limited our ability 
to detect an effect of SSRIs on risk of colorectal cancer within our study population, as a 
majority of SSRI users had been using SSRIs for less than two years (n=2,886). Further, current 
medications that were brought in and recorded were required to have been taken for a minimum 
of two weeks in order to be considered in our analysis. Although this may capture current use it 
does not capture consistency of use within the two week period, discontinued use soon after 
baseline assessment, or information on recency of use; our limited ability to verify use may have 
led in part to our null results. Previous studies which observed a null association may have been 
similarly limited by their ability to reliably capture past use, as participants could have been 
filling prescriptions and not taking prescribed ADs, or taking them inconsistently, 10, 11 possibly 
contributing to their null results. As both previous studies and our current analysis were limited 
by misclassification of use more information is needed to verify our results and explore the true 
effects of SSRIs.   
 An important limitation of previous studies is that none have controlled for the effects of 
depression in the relationship between AD use and colorectal cancer.8-12 As mentioned earlier 
about 78% of AD users are prescribed ADs for depression.5 Compared to healthy individuals, 
those with depression have higher levels of inflammatory markers, such as C-reactive protein, 
pro-inflammatory cytokines, and raised serum levels of interleukin-6 (IL6), interleukin-1 beta 
(IL1b), and tumor necrosis factor alpha (TNFa) potentially increasing risk of cancer.6,7 Prior 
studies support a relationship between depression and increased risk of overall cancer.14-17 Those 
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that looked at colorectal cancer observed an increased risk of colorectal cancer.7,15-17 A 
significant 40% increased risk of colorectal cancer was observed among those with depressive 
symptoms.7  Although this study did not control for AD use, its prospective design and large 
sample size give strength to the possibility that depression itself may be risk factor for colorectal 
cancer. Further, as depression is highly correlated to AD use and studies have shown depression 
may be associated with the development of colorectal cancer, if we did not control for depression 
it might appear that ADs increase risk of colorectal cancer or attenuate our ability to observe a 
relationship. Conversely, in our analysis models that controlled for age and BMI versus models 
that controlled for age, BMI, and depressive symptoms saw little change in the magnitude of 
effect of AD use on risk of colorectal cancer. Our ability to fully control for the effects of 
depression may be limited as we could only control for the effects of depressive symptoms, 
which, although our method of detection had a high sensitivity and specificity differ from the 
gold standard, a clinical diagnosis.  This may have led to some residual confounding within our 
observed results.    
To determine the independent effects of depression and AD use on risk of colorectal 
cancer. To our knowledge, this is the first study to examine the separate and combined 
relationship between depressive symptoms and AD use and colorectal cancer risk. We observed 
an increased colorectal cancer risk among women experiencing depressive symptoms without 
AD use (HR 1.21, 95% CI: 1.05-1.4) compared to women with neither depressive symptoms nor 
AD use.  This is important as it corroborates that women with depression may have an increased 
risk of colorectal cancer particularly among those not using AD medications.  
The biological mechanism through which TCA may act is unclear. In vitro studies of the 
effects of TCAs on human carcinoma cell lines have shown evidence to support both an increase 
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and decrease in the risk of colorectal cancer.12 TCAs were examined in an in vitro model of 
Human HT29 colon adenocarcinoma cells using three TCA drugs, imipramine, desipramine, and 
amitriptyline.30  All three of these TCA drugs exhibited cytotoxic effects acting through a non-
mitchondrial pathway associated with cell cycle progression, suggesting this effect is specific to 
malignant colorectal tumors.30 In order for this to occur it is necessary for the drug to reach 
cytotoxic levels within the cell, ~10µm. It still remains to be seen if oral use of TCA drugs can 
achieve cytotoxic levels in colorectal colon and rectal tissues; 30 however, our results of a 
possible protective association may indicate that cytotoxic levels can be reached in human 
subjects. Conversely, in rat models of colorectal cancer using the TCA, desipramine, serum 
levels of norepinephrine increased the proliferation of colon epithelial cells, indicating a 
carcinogenic effect.31 These results show that TCA composition and type may matter in terms of 
the carcinogenic or cytotoxic effect.12 As information on TCA composition, type, and 
genotoxicity was unavailable, our study is limited in its capability to determine the protective 
effects of specific TCA drugs, but is indicative of a possible cytotoxic mechanism of overall 
TCA use. Although our results show no association between SSRI use and risk of colorectal 
cancer, laboratory studies support protective effects of SSRIs on colorectal cancer. One such 
study observed reduced tumor cell growth after administering SSRIs to mice xenografted with 
human colorectal carcinomas compared to controls, indicating possible cytotoxic effect of 
SSRIs.8 In human colorectal cancer cell line a similar effect was observed when treated with 
SSRIs.8 Serotonin levels have been hypothesized to play a role in colon cancer, as serotonin 
levels promote cell division of adenocarcinomas of the large intestine. SSRIs inhibit the uptake 
of serotonin, reducing the mitotic rate of tumor cells within the colon.12, 13  
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Limitations of this study primarily relate to our measurement of AD use and depressive 
symptoms and our power. Null results observed with SSRI use and risk of colorectal cancer may 
relate to the fact that SSRI drugs were new to the market at the time of WHI baseline. In general, 
TCA use to treat depression was greater prior to 1995 and SSRI use for treatment of depression 
was greater after 1995.  As our analysis only assessed AD use at baseline we lack the ability to 
see if a recency of SSRI use may have led to our null results. Additionally, we had small 
numbers to detect an association between duration of use and risk of colorectal cancer for TCAs 
and other ADs.  Further we had small numbers of AD users who developed rectal cancer which 
limited our ability to detect an effect of AD use on risk of rectal cancer. To ascertain current 
medication use, women in the WHI brought in pill bottles of current medications and 
supplements.  This is advantageous as it is an accurate way to measure current use; however, if 
women failed to bring in their pill bottles we may have some misclassification and numbers may 
be underestimated. Furthermore, this method lacks the ability to capture specific information on 
chemical make-up, past use, dose, and intensity.  Although names of the specific ADs were 
available and may give some information on aspects of chemical make-up, this information was 
not used for this analysis, and as such we were unable to account for any effects. Additionally, 
duration of use was based on self-report, and as such are subject to some recall error, and does 
not reliably capture past use or adherence.  Therefore, our results for duration of use should be 
interpreted with caution. Depressive symptoms were measured according to a self-administered 
questionnaire from which a CES-D score was calculated. Although this method has high levels 
of sensitivity and specificity, it differs from the gold standard of a clinical diagnosis. Thus, the 
inability to accurately control for depression lead to residual confounding which may have 
attenuated the true relationship between AD use and risk of colorectal cancer.  
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Strengths of our study include its prospective design, large sample size, and 
comprehensive data on potential confounders.  Data for this study contained extensive 
information on depressive symptoms, history of a previous colonoscopy, diet, and BMI, which 
had not been previously controlled for, this limited potential confounding within our study.  
Further, as mentioned previously, the methods use in this study showed increased accuracy of 
actual, current AD use. 
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CHAPTER 5 
CONCLUSION 
In summary, our results support a slightly suggestive inverse association between TCA 
use and risk of colorectal cancer.  These findings contribute to a better understanding of the 
safety of AD use and provide some reassurance, as they suggest that AD use does not increase 
risk of colorectal cancer.  Given the high prevalence of depression and AD use, future work is 
needed to understand and verify these associations, and to explore the effects of SSRIs with more 
recent data is warranted. 
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Table 1. Distribution of Covariates According to AD use; Women's Health Initiative. 
Characteristic 
No Antidepressant 
Use 
N= 135,154  
Antidepressant 
User 
N=10,036 
Age; Mean (SD)  63.14(7.2) 62.01(7.2) 
Race & Ethnic Sub-population; (%)     
 Asian or Pacific Islander 3,812 (2.8) 77(0.8) 
 Black or African American 12,756 (9.5) 538(5.4) 
 Hispanic/Latino 5,548(4.1) 339(3.4) 
 White (not Hispanic origin) 110,560(82.0) 8,913(89.0) 
 Other 2,150(1.6) 144(1.4) 
Body Mass Index (BMI), kg/m2 (%)     
 Underweight (<18.5) 1,155(0.9) 75(0.8) 
 Normal (18.5-<24.9) 46,425(34.6) 2,771(27.9) 
 Overweight (>=24.9-<30) 46,658(34.8) 3,414(34.3) 
 Obese I (30-34.9) 24,712(18.4) 2,025(20.4) 
 Obese II (35.0-39.9) 9,925(7.4) 1,037(10.4) 
 Extreme Obesity (>=40) 5,129(3.8) 621(6.3) 
Healthy Eating Index Score (%)     
 Less than 60.05 33,666(25.0) 2,762(27.6) 
 60.05-68.63 33,868(25.1) 2,493(24.9) 
 68.634-75.66 33,759(25.0) 2,468(24.6) 
 75.66 or Greater 33,609(24.9) 2,296(22.9) 
Physical Activity MET (hours/week) (%)     
 <2.25(hours/ week) 31,853(24.8) 3,143(32.7) 
 2.3-8.3(hours/week) 32,220(25.1) 2,465(25.6) 
 8.375-17.75(hours/week) 31,905(24.9) 2,168(22.6) 
 Greater Than 17.83(hours/week) 32,422(25.3) 1,838(19.1) 
Alcohol (%)     
 None  14,956(11.2) 963(9.7) 
 Past 24,022(17.9) 2,622(26.3) 
 <1 Drink/Month 16,732(12.5) 1,276(12.8) 
 <1 Drink per Week 27,638(20.6) 2,004(20.1) 
 1 to <7 Drinks per Week 34,965(26.1) 2,158(21.7) 
 Greater than 7 Drinks per Week 15,821(11.8) 939(9.4) 
Smoking (Pack-years) (%)     
 Never 69,069(51.8) 4,477(45.3) 
 <5 Pack-years 18,872(14.1) 1,406(14.2) 
 5-20 Pack-years 18,766(14.1) 1,396(13.8) 
 Greater than 20 Pack-years 23,628(17.7) 2,418(24.4) 
 Don't Know Duration of Smoking 3,087(2.3) 222(2.2) 
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Table 1. (cont’d) Distribution of Covariates According to AD use; Women's Health 
Initiative. 
Characteristic 
No Antidepressant 
Use 
N= 135,154 
Antidepressant User 
N=10,036 
Has a Primary Care Provider (%) 124,894(93.3) 9,739(97.8) 
Has Had a Medical Visit (within 1 year) (%) 105,461(80.8) 8,958(91.5) 
History of Diabetes (%) 7,515(5.6) 854(8.5) 
History of Diverticulitis (%) 9,982(7.9) 1,119(11.8) 
History of Hypertension (%) 44,181(32.7) 4,047(40.3) 
Colonoscopy  
(colonoscopy, sigmoidoscopy or flex sig) (%) 
    
 No 64,091(50.1) 3,627(37.9) 
 <5 years ago 39,614(31.0) 3,935(41.1) 
 >5 years ago 23,940(18.7) 1,995(20.8) 
 Yes, unsure of date 235(0.2) 19(0.2) 
Has had Polyps of Colon Removed (%) 10,623(16.7) 1,117(18.8) 
Depressive Symptoms (CES-D scale)     
 Not Depressed (< 0.06) 119,126(90.6) 6,882(70.9) 
 Depressed (>=0.06) 12,389(9.4) 2,832(29.1) 
Postmenopausal Hormone Therapy History (%)     
 Never 60,307(44.6) 2,807(28.0) 
 Past, Estrogen-alone 12,682(9.4) 988(9.8) 
 Past, Estrogen and Progesterone  8,002(5.9) 669(6.7) 
 Current Estrogen alone 29,541(21.9) 3,318(33.1) 
 Current Estrogen and Progesterone 24,621(18.2) 2,254(22.5) 
Nonsteroidal Anti-inflammatory Drug (NSAID) 
use (%) 
    
 Never  80,716(59.7) 4,653(46.4) 
 Use for up to 1 Year  16,962(12.5) 1,618(16.1) 
 1-3 years 12,377(9.2) 1,193(11.9) 
 3-8 years 11,652(8.6) 1,235(12.3) 
 8-20 years 9,578(7.1) 1,020(10.2) 
 Greater than 20 Years 3,869(2.9) 317(3.2) 
First Degree Relative had Colorectal Cancer (%) 20,267(15.7) 1,453(15.2) 
HRT Study Arm (%)     
 Not randomized to HRT 110,223(81.6) 8,586(85.6) 
 Estrogen alone intervention 4,719(3.5) 328(3.3) 
 Estrogen alone Control 4,771(3.5) 330(3.3) 
 Estrogen and Progesterone Intervention 7,916(5.9) 396(4.0) 
 Estrogen and Progesterone Control 7,525(5.6) 396(4.0) 
*-Percentages may not add to 100 because of missing 
data     
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Table 2. Distribution of Antidepressant Subtype Use Among Antidepressant Users 
(N=10,036); Women’s Health Initiative. 
  
Antidepressant Class N (%) 
    
SSRI Use    
Non-User 4,908(48.9) 
SSRI User 5,128(51.1) 
Up to 2 Years of Use  2,886(28.8) 
Greater than 2 years of Use 2,242(22.3) 
    
TCA Use (%)   
Non-User 5,954(59.3) 
TCA User 4,082(40.7) 
 Up to 2 Years of Use 1,546(15.4) 
 Greater than 2 years of Use 2,536(25.3) 
    
Other Antidepressant (AD) Use (%)   
Non-User 8,521(84.9) 
Other AD User 1,515(15.1) 
 Up to 2 Years of Use  803(8.0) 
 Greater than 2 years of Use 712(7.1) 
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Table 3. Distribution of Colorectal Cancer According to Antidepressant Use; Women’s Health 
Initiative 
Total Cancer 
No Antidepressant 
Use 
Antidepressant 
User P-Value* 
Colorectal cancer      0.018 
No  132,722(98.2) 9,888(98.5)   
Yes 2,432(1.8) 148(1.5)   
        
Colon Cancer     0.053 
No  133,130(98.5) 9,910(98.7)   
Yes 2,024(1.5) 126(1.3)   
        
Recto sigmoid Cancer       
No  135,011(99.9) 10,030(99.5) 0.196 
Yes 143(0.1) 6(0.1)   
        
Rectal Cancer       
No 134,831(99.8) 10,018(99.8) 0.234 
Yes 323(0.2) 18(0.2)   
*chi-square tests for categorical variables, T tests for continuous variables. For variables with 
small cell size Fischer's exact test 
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Table 4. Age and Multivariable Adjusted HRs and 95% Confidence intervals of Baseline AD use and Colorectal Cancer; WHI.       
 
  
  Age-adjusted  
 
BMI-adjusted*     
  
Depression- 
Adjusted** 
  Adjusted† 
 
 
  HR 95% CI   HR 95% CI 
 
HR 95% CI   HR 95% CI 
Total Colorectal Cancer Cases 
Person- 
Years 
 
              
 
    
  N=2,580   N=2,197   N=2,197   N=2,197   N=2,197 
AD use (SSRI and TCA)  123 42,764,833 0.90 .75-1.08   0.88 0.73-1.05   0.84 0.70-1.01   0.90 0.75-1.09 
AD duration                           
Less than 2 Years of Use  56 20,475,508 0.87 0.66-1.13   0.85 0.65-1.10   0.80 0.61-1.04   0.85 0.65-1.11 
Greater Than 2 Years of Use 67 22,289,325 0.93 0.73-1.19   0.91 0.71-1.16   0.88 0.69-1.11   0.95 0.75-1.22 
SSRI use 73 22,111,189 1.10 0.87-1.38   1.06 0.84-1.34   1.00 0.79-1.27   1.08 0.85-1.36 
SSRI duration                           
Less than 2 Years of Use  44 12,305,981 1.18 0.87-1.59   1.15 0.85-1.55   1.08 0.79-1.45   1.14 0.85-1.55 
Greater Than 2 Years of Use 29 9,805,208 0.99 0.69-1.43   0.95 0.66-1.37   0.92 0.63-1.32   0.99 0.68-1.43 
TCA use 43 17,160,382 0.74 0.55-1.00   0.72 0.54-0.98   0.71 0.52-0.96   0.76 0.56-1.03 
TCA duration                           
Less than 2 Years of Use  9 6,558,417 0.41 0.21-0.79   0.40 0.21-0.78   0.40 0.21-0.76   0.42 0.22-0.81 
Greater Than 2 Years of Use 34 10,601,965 0.94 0.67-1.31   0.92 0.65-1.29   0.90 0.64-1.26   0.97 0.69-1.37 
Other Antidepressant (AD) 
use 12 6,365,452 0.62 0.35-1.10   0.61 0.35-1.08   0.57 0.33-1.0   0.63 0.35-1.11 
Other AD Duration                            
Less than 2 Years of Use  5 3,380,000 0.50 0.21-1.20   0.48 0.20-1.16   0.45 0.19-1.08   0.47 0.19-1.13 
Greater Than 2 Years of Use 7 2,985,452 0.76 0.36-1.59   0.76 0.36-1.59   0.72 0.34-1.51   0.82 0.39-1.73 
*Adjusted for age and BMI                           
**Adjusted for age, BMI, and depression (CES-D scale) 
†Adjusted for age, HRT clinical trial study arm, BMI, health eating index (hei2005), physical activity, smoking, diabetes history, hypertension history, colonoscopy, polyp removal, 
depression (CES-D), family history of colorectal cancer, hrt use, history of diverticulitis, NSAID use   
 
Table 5. Age and Multivariable adjusted HRs and 95% Confidence intervals of Baseline AD use and Colon Cancer; WHI.  
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Age-adjusted  BMI-adjusted*     
Depression- 
Adjusted** 
Adjusted† 
Total Colon Cancer Cases (%) 
Person- 
Years HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
  N=2,150   N=1842 N=1842 N=1842 N=1842 
AD use (SSRI and TCA) 104 42,764,833 0.92 .75-1.12 0.89 0.73-1.09 0.85 0.7-1.04 0.91 0.74-1.12 
AD duration               
Less than 2 Years of Use  48 20,475,508 0.90 0.67-1.19 0.87 0.66-1.16 0.82 0.62-1.10 0.87 0.65-1.16 
Greater Than 2 Years of Use 56 22,289,325 0.94 0.72-1.22 0.91 0.7-1.19 0.88 0.67-1.15 0.95 0.73-1.25 
SSRI use 66 22,111,189 1.20 0.94-1.54 1.16 0.91-1.49 1.10 0.86-1.40 1.17 0.91-1.50 
SSRI duration                     
Less than 2 Years of Use  40 12,305,981 1.30 0.95-1.77 1.26 0.92-1.73 1.18 0.86-1.6 1.25 0.91-1.72 
Greater Than 2 Years of Use 26 9,805,208 1.08 0.73-1.59 1.04 0.7-1.53 0.99 0.67-1.47 1.06 0.72-1.57 
TCA use 32 17,160,382 0.66 0.46-0.93 0.64 0.45-0.91 0.63 0.44-0.89 0.68 0.48-0.96 
TCA duration                     
Less than 2 Years of Use  7 6,558,417 0.38 0.18-0.8 0.37 0.18-0.79 0.37 0.17-0.77 0.39 0.19-0.82 
Greater Than 2 Years of Use 25 10,601,965 0.82 0.55-1.22 0.8? 0.54-1.19 0.79 0.53-1.17 0.85 0.57-1.26 
Other Antidepressant (AD) use 9 6,365,452 0.56 0.29-1.09 0.55 0.29-1.07 0.52 0.27-1.00 0.56 0.29-1.08 
Other AD Duration                     
Less than 2 Years of Use  3 3,380,000 0.36 0.12-1.12 0.35 0.11-1.09 0.32 0.1-1.00 0.34 0.11-1.05 
Greater Than 2 Years of Use 6 2,985,452 0.78 0.35-1.75 0.78 0.35-1.74 0.74 0.33-1.66 0.84 0.38-1.87 
                      
*Adjusted for age and BMI                     
**Adjusted for age, BMI, and depression (CES-D scale)  
†Adjusted for age, HRT clinical trial study arm, BMI, health eating index (hei2005), physical activity, smoking, diabetes history, hypertension history, colonoscopy, polyp 
removal, depression (CES-D), family history of colorectal cancer, hrt use, history of diverticulitis, NSAID use  
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Table 6. Age and Multivariable Adjusted HRs and 95% Confidence intervals of Baseline AD use and Rectal Cancer; WHI.   
    
  Age-adjusted  
 
BMI-adjusted*     
  
Depression- 
Adjusted** 
  Adjusted† 
Total Rectal Cancer Cases (%) 
Person- 
Years HR  95% CI    HR 95% CI   HR    95% CI 
 
 HR  95% CI 
  N=482   N=403   N=403   N=403   N=403 
AD use (SSRI and TCA) 21 42,764,833 0.8 0.52-1.24   0.78 0.50-1.21   0.76 0.49-1.18   0.84 0.54-1.31 
AD duration                           
Less Than 2 Years of Use  8 20,475,508 0.64 0.32-1.30   0.63 0.31-1.27   0.6 0.30-1.22   0.66 0.33-1.33 
Greater than 2 years of Use 13 22,289,325 0.94 0.54-1.64   0.92 0.53-1.60   0.9 0.51-1.56   1 0.58-1.76 
SSRI use 8 22,111,189 0.61 0.3-1.22   0.59 0.29-1.19   0.56 0.28-1.14   0.62 0.31-1.27 
                            
SSRI duration                           
Less Than 2 Years of Use  4 12,305,981 0.55 0.20-1.46   0.53 0.20-1.42   0.5 0.19-1.36   0.55 0.20-1.48 
Greater than 2 years of Use 4 9,805,208 0.69 0.26-1.84   0.66 0.25-1.77   0.64 0.24-1.72   0.72 0.27-1.94 
TCA use 12 17,160,382 1.12 0.63-1.98   1.09 0.62-1.94   1.08 0.61-1.92   1.19 0.67-2.13 
TCA duration                           
Less Than 2 Years of Use  2 6,558,417 0.49 0.12-1.98   0.49 0.12-1.95   0.48 0.12-1.92   0.53 0.13-2.12 
Greater than 2 years of Use 10 10,601,965 1.49 0.80-2.79   1.46 0.78-2.73   1.45 0.77-2.71   1.6 0.85-3.00 
Other Antidepressant (AD) 3 6,365,452 0.8 0.26-2.49   0.79 0.25-2.45   0.76 0.24-2.37   0.84 0.27-2.64 
Other AD Duration                           
Less Than 2 Years of Use  2 3,380,000 1.02 0.25-4.09   0.99 0.25-3.97   0.95 0.23-3.81   1 0.25-4.04 
Greater than 2 years of Use 1 2,985,452 0.56 0.08-3.98   0.56 0.78-3.97   0.54 0.08-3.87   0.64 0.09-4.59 
*Adjusted for age and BMI   
**Adjusted for age, BMI, and depression (CES-D scale) 
†Adjusted for age, HRT clinical trial study arm, BMI, health eating index (hei2005), physical activity, smoking, diabetes history, hypertension history, colonoscopy, polyp removal, 
depression (CES-D), family history of colorectal cancer, hrt use, history of diverticulitis, NSAID use   
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Table 7. Multivariable adjusted HRs and 95% Confidence Intervals for the Joint Distribution of Depressive Symptoms and AD 
use at Baseline and risk of Colorectal Cancer; WHI.  
  
Group 
Colorectal 
Cancer Cases, N 
Person- Years 
Adjusted† 
HR (95% CI) 
          
Healthy (Non-user, No Depressive Symptoms) 1,865 549,400,000 1.00 (Ref) 
          
Untreated (Non-user, Depressive Symptoms) 209 51,982,035 1.21 1.05-1.4 
          
Treated (AD User, No Depressive Symptoms) 85 30,638,454 0.91 0.73-1.13 
          
Insufficient Treatment (AD User, Depressive Symptoms) 38 12,126,379 1.08 0.78-1.49 
          
†Adjusted for age, HRT clinical trial study arm, BMI, health eating index (hei2005), physical activity, smoking, diabetes history, hypertension history, colonoscopy, polyp 
removal, family history of colorectal cancer, hrt use, history of diverticulitis, NSAID use  
 *NOTE: interaction p=0.92 
  
  
  
  
  
  
  
  
  
 
  
29 
 
BIBILIOGRAPHY 
 
 
1. American Cancer Society. Cancer Facts & Figures 2015. Available at URL: 
http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-
044552.pdf  
 
 
2. Pratt, L. A., Brody, D. J., & Gu, Q. (2011). Antidepressant use in persons aged 12 and 
over: United States, 2005-2008. 
 
 
3. Olfson, M., & Marcus, S. C. (2009). National patterns in antidepressant medication 
treatment. Archives of general psychiatry, 66(8), 848-856. 
 
 
4. Bahl, S., Cotterchio, M., & Kreiger, N. (2003). Use of antidepressant medications and the 
possible association with breast cancer risk.Psychotherapy and psychosomatics, 72(4), 
185-194. 
 
 
5. Loosbrock, D. L., Tomlin, M. E., Robinson, R. L., Obenchain, R. L., & Croghan, T. W. 
(2002). Appropriateness of prescribing practices for serotonergic 
antidepressants. Psychiatric Services. 
 
 
6. Archer, J. A., Hutchison, I. L., Dorudi, S., Stansfeld, S. A., & Korszun, A. (2012). 
Interrelationship of depression, stress and inflammation in cancer patients: A preliminary 
study. Journal of affective disorders, 143(1), 39-46. 
 
 
7. Kroenke, C. H., Bennett, G. G., Fuchs, C., Giovannucci, E., Kawachi, I., Schernhammer, 
E., ... & Kubzansky, L. D. (2005). Depressive symptoms and prospective incidence of 
colorectal cancer in women. American Journal of Epidemiology, 162(9), 839-848. 
 
 
8.  Chubak, J., Boudreau, D. M., Rulyak, S. J., & Mandelson, M. T. (2011). Colorectal 
cancer risk in relation to antidepressant medication use. International Journal of Cancer, 
128(1), 227-232. 
 
 
9. Coogan, P. F., Strom, B. L., & Rosenberg, L. (2009). Antidepressant use and colorectal 
cancer risk. Pharmacoepidemiology and drug safety, 18(11), 1111-1114. 
 
 
30 
 
10. Cronin-Fenton, D. P., Riis, A. H., Lash, T. L., Dalton, S. O., Friis, S., Robertson, D., & 
Sørensen, H. T. (2011). Antidepressant use and colorectal cancer risk: a Danish 
population-based case–control study. British journal of cancer, 104(1), 188-192. 
 
 
11. Haukka, J., Sankila, R., Klaukka, T., Lonnqvist, J., Niskanen, L., Tanskanen, A., ... & 
Tiihonen, J. (2010). Incidence of cancer and antidepressant medication: record linkage 
study. International Journal of Cancer, 126(1), 285-296. 
 
 
12. Xu, W., Tamim, H., Shapiro, S., Stang, M. R., & Collet, J. P. (2006). Use of 
antidepressants and risk of colorectal cancer: a nested case-control study. The lancet 
oncology, 7(4), 301-308. 
 
 
13. Ataee, R., Ajdary, S., Rezayat, M., Shokrgozar, M. A., Shahriari, S., & Zarrindast, M. R. 
(2010). Study of 5HT3 and HT4 receptor expression in HT29 cell line and human colon 
adenocarcinoma tissues. Archives of Iranian medicine, 13(2), 120-125. 
 
 
14. Linkins RW, Comstock GW. Depressed mood and development of cancer. Am J 
Epidemiol 1990;132:962–72. 49. 
 
 
15.  Kaplan GA, Reynolds P. Depression and cancer mortality and morbidity: prospective 
evidence from the Alameda County Study. J Behav Med 1988;11:1–13. 50. 
 
 
16.  Gallo JJ, Armenian HK, Ford DE, et al. Major depression and cancer: the 13-year 
follow-up of the Baltimore Epidemiologic Catchment Area sample (United States). 
Cancer Causes Control 2000;11:751–8 
 
 
17. Dalton SO, Mellemkjaer L, Olsen JH, et al. Depression and cancer risk: a register-based 
study of patients hospitalized with affective disorders, Denmark, 1969–1993. Am J 
Epidemiol 2002;155:1088–95. 
 
 
18. Hays, J., Hunt, J. R., Hubbell, F. A., Anderson, G. L., Limacher, M., Allen, C., & 
Rossouw, J. E. (2003). The Women's Health Initiative recruitment methods and 
results. Annals of epidemiology, 13(9), S18-S77. 
 
 
19. Women’s Health Initiative. Form 44. Available at URL: 
https://www.whi.org/researchers/studydoc/WHI%20Forms/F044%20v4.pdf 
 
31 
 
20. Lakey, S. L., LaCroix, A. Z., Gray, S. L., Borson, S., Williams, C. D., Calhoun, D., ... & 
Coday, M. (2012). Antidepressant use, depressive symptoms, and incident frailty in 
women aged 65 and older from the Women's Health Initiative Observational 
Study. Journal of the American Geriatrics Society, 60(5), 854-861. 
 
21. Curb, J. D., Mctiernan, A., Heckbert, S. R., Kooperberg, C., Stanford, J., Nevitt, M., ... & 
Daugherty, S. (2003). Outcomes ascertainment and adjudication methods in the Women's 
Health Initiative. Annals of epidemiology, 13(9), S122-S128. 
 
 
22. Tabung, F. K., Steck, S. E., Ma, Y., Liese, A. D., Zhang, J., Caan, B., ... & Wactawski-
Wende, J. (2015). The association between dietary inflammatory index and risk of 
colorectal cancer among postmenopausal women: results from the Women’s Health 
Initiative. Cancer Causes & Control, 26(3), 399-408. 
 
 
23. Gorczyca, A. M., He, K., Xun, P., Margolis, K. L., Wallace, J. P., Lane, D., ... & Luo, J. 
(2015). Association between magnesium intake and risk of colorectal cancer among 
postmenopausal women. Cancer Causes & Control,26(12), 1761-1769. 
 
 
24. Burnam, M. A., Wells, K. B., Leake, B., & Landsverk, J. (1988). Development of a brief 
screening instrument for detecting depressive disorders. Medical care, 775-789. 
 
 
25. Tuunainen, A., Langer, R. D., Klauber, M. R., & Kripke, D. F. (2001). Short version of 
the CES-D (Burnam screen) for depression in reference to the structured psychiatric 
interview. Psychiatry research, 103(2), 261-270. 
 
 
26. Bertone-Johnson, E. R., Powers, S. I., Spangler, L., Brunner, R. L., Michael, Y. L., 
Larson, J. C., ... & Wassertheil-Smoller, S. (2011). Vitamin D intake from foods and 
supplements and depressive symptoms in a diverse population of older women. The 
American journal of clinical nutrition, 94(4), 1104-1112. 
 
 
27. Spangler, L., Scholes, D., Brunner, R. L., Robbins, J., Reed, S. D., Newton, K. M., ... & 
LaCroix, A. Z. (2008). Depressive symptoms, bone loss, and fractures in postmenopausal 
women. Journal of general internal medicine,23(5), 567-574. 
 
 
28. Aran, V., Victorino, A. P., Thuler, L. C., & Ferreira, C. G. (2016). Colorectal Cancer: 
Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and 
Mortality. Clinical colorectal cancer. 
 
 
32 
 
29. Bassuk, S. S., & Manson, J. E. (2015). Oral contraceptives and menopausal hormone 
therapy: relative and attributable risks of cardiovascular disease, cancer, and other health 
outcomes. Annals of epidemiology, 25(3), 193-200. 
 
 
30. Arimochi, H., & Morita, K. (2006). Characterization of cytotoxic actions of tricyclic 
antidepressants on human HT29 colon carcinoma cells. European journal of 
pharmacology, 541(1), 17-23. 
 
 
31. Iishi, H., Tatsuta, M., Baba, M., & Taniguchi, H. (1993). Enhancement by the tricyclic 
antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by 
azoxymethane. Carcinogenesis, 14(9), 1837-1840. 
 
 
